Unlocking the therapeutic potential of artificial metalloenzymes
Unlocking the therapeutic potential of artificial metalloenzymes
复制标题
DOI：
10.2183/pjab.96.007
复制
发表时间：
2020-03
期刊：
影响因子：
--
通讯作者：
Katsunori Tanaka;Kenward Vong
中科院分区：
文献类型：
--
作者：
Katsunori Tanaka;Kenward Vong
为了利用金属的功能，自然界已经进化了数十亿年，利用金属蛋白作为许多细胞过程的关键成分。尽管如此，过渡金属如钌、钯、铱和金在天然存在的金属蛋白中基本上不存在，可能是由于它们作为贵金属的稀缺性。为了模仿自然界的进化过程，人工金属酶（ArMs）领域诞生了，以从生物环境中过渡金属独特的化学选择性和正交性中获益。在目前的状态下，许多例子已经成功地将过渡金属纳入各种蛋白质支架中。使用这些ArMs，已经进行了许多新的自然反应的例子，其中一些已经显示出相当大的生物相容性。鉴于这一领域的快速增长，本次审查的目的是突出一些重要的研究，已经开始采取下一步在这一领域内，即开发ArM为中心的药物疗法或生物技术工具。
In order to harness the functionality of metals, nature has evolved over billions of years to utilize metalloproteins as key components in numerous cellular processes. Despite this, transition metals such as ruthenium, palladium, iridium, and gold are largely absent from naturally occurring metalloproteins, likely due to their scarcity as precious metals. To mimic the evolutionary process of nature, the field of artificial metalloenzymes (ArMs) was born as a way to benefit from the unique chemoselectivity and orthogonality of transition metals in a biological setting. In its current state, numerous examples have successfully incorporated transition metals into a variety of protein scaffolds. Using these ArMs, many examples of new-to-nature reactions have been carried out, some of which have shown substantial biocompatibility. Given the rapid rate at which this field is growing, this review aims to highlight some important studies that have begun to take the next step within this field; namely the development of ArM-centered drug therapies or biotechnological tools.